Drug resistance remains a serious limiting factor in the treatment of acute myeloid leukaemia (AML) either at initial presentation or following primary or subsequent relapses. Using specific kinase inhibitors, this study has investigated the contribution of the Ras/PI3-kinase regulated survival pathways to drug resistance and suppression of apoptosis in a cell line derived from AML (HL60). Inhibition of the Raf/MAP-kinase (ERK) pathway with a specific MAP-kinase inhibitor, apigenin did not sensitise HL60 cells to drug-induced apoptosis, indicating a lack of involvement in chemoresistance. In contrast, the PI3-kinase inhibitors, LY294002 and wortmannin, did induce a significant increase in apoptosis in combination with cytotoxic drugs. The contribution of downstream mediators of PI3-kinase, p70S6-kinase and PKB/Akt were then investigated. While inhibition of p70S6-kinase with rapamycin did not increase drug-induced apoptosis, PI3-kinase inhibition resulted in notable dephosphorylation of PKB, suggesting that the PI3-kinase/PKB survival pathway may play a major role in chemoresistance in AML. This pathway has been reported to mediate heterodimer interactions with the proapoptotic regulator, Bad. In contrast to previous studies, we found no evidence of Bad binding to anti-apoptotic Bcl-2, Bcl-X L or Mcl-1, or of alterations in Bax heterodimers. This suggests that alternative targets of PI3-kinase/PKB, distinct from the Bcl-2 family may be responsible for contributing to survival factor-mediated drug resistance in AML. Leukemia (2000) 14, 602-611.
Introduction
The successful treatment of acute myeloid leukaemia (AML) is frequently impeded by the development of resistance to a wide spectrum of cytotoxic drugs. Drug resistance is a consequence of failure of leukaemic cells to engage apoptosis in the presence of cytotoxic drugs. Apoptosis is an energy requiring suicide programme, which is normally activated in response to cellular damage, or following physiological signals such as death receptor ligation or withdrawal of survival signals. 1, 2 Previously studied mechanisms employed by a variety of cells to export or neutralise anti-neoplastic drugs, include p-glycoprotein, 3 the multi-drug resistance-associated protein, 4 and glutathione S-transferases. 5 By effectively reducing the intracellular concentration of drugs, these mechanisms increase cellular tolerance and suppress the normal apoptotic response. Despite several studies reporting an association between drug export and drug resistance in leukaemia, it is apparent that such mechanisms cannot fully account for drug resistance in AML. 6 In this study we addressed the question of whether the exploitation of survival pathways, which may have contributed to disease development in the first instance, may also be important for attributing a drug-resistant phenotype in AML. The signalling molecule Ras is involved in growth, survival, differentiation and apoptosis, in many cell types. [7] [8] [9] Ras is activated by interaction of cytokines such as interleukin-2, epidermal growth factor and platelet-derived growth factor, with their cell surface receptor, inducing binding of guanosine triphosphate (GTP) to Ras and subsequent activation of downstream kinases Raf-1 and extracellular signal related kinases (ERK). 10, 11 Binding of GTP to Ras, and subsequent inactivation by hydrolysis to guanosine diphosphate (GDP) is a tightly regulated event orchestrated primarily by guanine-nucleotide exchange factors (GEFs) 12 and GTPase-activating proteins (GAPs), 13 positive and negative regulators of Ras, respectively. Ras has been reported to be mutated in 30% of leukaemias, most frequently acute leukaemias. 14, 15 It is likely that this frequency of Ras deregulation in leukaemia is greatly underestimated as deregulation of GEFs 12 or GAPs, 13 overexpression of growth factor receptors, 16 or autonomous cytokine production, 17 may all lead to constitutive signalling of Ras, without mutations in Ras itself. Efforts to elucidate the precise role of Ras in leukaemia have yielded conflicting reports, as to whether deregulated signalling is an initiating factor of leukaemogenesis, 18 or whether mutations accumulate only as the disease progresses. 19 Despite this debate, deregulation of Ras or its signalling pathways is considered to contribute to disease aggression, chemoresistance, immune evasion and reduced patient survival. 15, 20 Furthermore, Ras is reputed to upregulate expression of the viability promoting molecule Bcl-2 21 often elevated in myeloid leukaemias 22 where it promotes tumour survival, contributes to drug resistance and is considered a poor prognostic marker for clinical outcome. 23 A recognised distinction has been made between mitogenic and survival pathways, in that many previously recognised mitogens are now considered to be survival factors, promoting survival separately from proliferation, eg IL-3. [24] [25] [26] One of the best characterised of these pathways is initiated by binding of IL-3 to its cell surface receptor resulting in rapid activation of a specific kinase cascade, from phosphatidylinositol-3-kinase (PI3-kinase) to protein kinase B (PKB) and Bad. Bad is a proapoptotic member of the Bcl-2 family, unique in exerting its influence by binding to an anti-apoptotic member of the family such as Bcl-X L on inhibition of this kinase cascade. When PI3-kinase and PKB are active, Bad is phosphorylated and sequestered to the cytosolic protein, 14-3-3, away from Bcl-X L resulting in survival. [27] [28] [29] In light of the current literature concerning Ras and leukaemia, we dissected the signalling pathways downstream of Ras and asked whether or not these pathways were contributing to chemoresistance and the suppression of apoptosis in leukaemia. Downstream mediators of Ras have previously been implicated in survival. Raf has been reported to protect myeloid cells from apoptosis induced by growth factor withdrawal 30 possibly by co-operation with Bcl-2. 31 The ERK cascade can inhibit apoptosis on removal of survival factor.
32 PI3-kinase has been shown to exert a strong survival signal, which is often cell type and stimulus dependent. 25, 26 In addition to 603 its activation by stimulated growth factor receptors, PI3-kinase may also be activated by interaction with Ras in a GTP-dependent manner. 33, 34 p70S6-kinase, another downstream mediator of PI3-kinase has also previously been reported to have anti-apoptotic function.
35 p70S6-kinase is responsible for the phosphorylation and activation of the 40S ribosomal protein S6, essential for progression through the G1 phase of the cell cycle. 36 To investigate these survival pathways and their importance in impeding apoptosis, we used the acute pro-myeloid leukaemic cell line, HL60, which has an activating N-Ras mutation. 37, 38 Furthermore, HL60 cells, although highly expressing Bcl-2 are unselected for enhanced resistance to cytotoxic drugs. 39 This is relatively uncommon in drug resistance studies which often employ cell lines which have been artificially selected for high levels of resistance to concentrations of drugs which may never be clinically relevant. We have taken the view that the HL60 cell line is already drug resistant. This cell line was established from a patient who had only a partial response to two initial courses of chemotherapy, and following subsequent disease progression and despite a third course of therapy, died within 10 weeks of referral. To investigate the role of survival pathways in drug resistance in leukaemic cells from this patient we have employed inhibitors specific to endogenous kinases in survival pathways. We demonstrate that PI3-kinase activity plays a significant role in drug resistance in AML, most likely through its downstream kinase effector PKB, but independently of the parallel ERK or p70S6-kinase cascades and of known Bcl-2 family interactions.
Materials and methods

Cell culture and reagents
The human promyeloid leukaemia cell line HL60 was maintained in RPMI 1640, supplemented with 10% foetal calf serum (FCS), 1% penicillin-streptomycin and 2 mm l-glutamine (all GIBCO, Paisley, UK). Cells were maintained at 37°C in a humidified 5% CO 2 atmosphere. Cytotoxic drugs, etoposide, camptothecin, actinomycin D and cycloheximide (Sigma, Poole, UK) and inhibitors, apigenin, LY294002, wortmannin and rapamycin (Calbiochem, Nottingham, UK) were prepared in DMSO (Sigma). Doxorubicin and mitoxantrone (Sigma) were prepared in millipore H 2 O and ethanol, respectively.
Induction and assessment of apoptosis
For the induction of apoptosis by cytotoxic drugs, cells (2.5 × 10 5 /ml) were seeded in 96-well plates and incubated for 4 h at 37°C with varying concentrations of cytotoxic drug. Kinase inhibition was achieved by incubating cells with relevant inhibitor for 5 min prior to cytotoxic drug addition. The PI3-kinase inhibitor, wortmannin was given a 1 h preincubation prior to drug addition, and subsequent addition every 2 h. Cell death was quantified by morphological assessment of stained cytospin preparations and also by flow cytometry. Rapi-diff (LanganBach Services, Wicklow, Ireland) stained cytocentrifuged cell preparations were examined for the morphological characteristics of apoptosis using previously defined criteria. 40 Morphological cell death was measured by counting three independent microscopic fields of at least 100 cells. The criLeukemia teria for cell death as measured by flow cytometry were based on changes in light scattering properties of dead cells due to cell shrinkage and increased granularity and also permeability to the DNA binding dye, propidium iodide (PI) (Sigma). 41 For PI uptake analysis, cells (2.5 × 10 5 /ml) were incubated with 5 g/ml PI at room temperature and analysed directly on a Becton Dickinson (Oxford, UK) FACScan using lysis II software. These cells were not harvested from synchronised populations at the same growth phase prior to every experiment. Thus, some variability is notable in the levels of apoptosis induced by camptothecin, an S-phase specific cytotoxin. 42 Cell lysis and immunoblotting 5 × 10 6 cells were lysed in 50 l of cell lysis buffer (50 mm Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mm NaCl, 1 mm EGTA, 1 mm Na 3 VO 4 , 1 mm NaF and protease inhibitor cocktail (1 g/ml antipain, 1 g/ml aprotinin, 1 g/ml chymostatin, 1 g/ml leupeptin, 1 g/ml pepstatin, 100 m PMSF)) for 20 min on ice. Protein extracts were cleared by centrifugation and protein concentration determined using Bio-rad protein assay reagent (Bio-rad, Munich, Germany). An equal volume of 2× SDS gel loading buffer (100 mm Tris-HCl (pH 6.8), 200 mm DTT, 4% SDS, 0.2% bromophenol blue and 20% glycerol) was added to samples and boiled for 10 min. Cell extracts were resolved by 10% SDS-PAGE and transferred to nitro-cellulose membranes (Schleicher and Schuell, Dessel, Germany). Membranes were blocked in 5% fat-free dried milk in Tris-buffered saline (TBS), and incubated overnight at 4°C with relevant primary antibody, either rabbit anti-PKB or anti-phosphoPKB (ser 473) polyclonal antibodies (pAb) (New England Biolabs, Beverly, MA, USA), murine anti-MAP kinase R2 (ERK 2) monoclonal antibody (mAb), (Upstate Biotechnology, Lake Placid, NY, USA) at 1:1000 dilution in blocking buffer, or rabbit anti-phosphoBad (Ser 136) pAb (New England Biolabs) at 1:500 dilution in blocking buffer. Phospho-and nonphospho-Bad control proteins were also supplied by New England Biolabs. After washing in TBS, membranes were incubated with antirabbit or anti-mouse immunoglobin horse-radish peroxidaseconjugated secondary antibodies (Dako, Glostrup, Denmark), 1000-fold diluted in blocking buffer for 1 h. Detection was performed using enhanced chemiluminescence (Amersham, Buckinghamshire, UK). Samples for the ERK inhibition assay were prepared as above but resolved by 6''SDS-PAGE gel (Biotec-Fisher, Reiskirchen, Germany) to detect alterations in electromobility shift due to ERK 2 phosphorylation status.
p70S6-kinase assay
Untreated and rapamycin-treated samples (10 × 10 6 cells) were lysed in 300 l buffer (50 mm Tris-HCl (pH 7.4), 1% NonidetP-40, 0.25% sodium deoxycholate, 150 mm NaCl, 1 mm EGTA, 1 mm Na 3 VO 4 , 1 mm NaF and protease inhibitor cocktail (as described above) for 20 min on ice. Lysate was cleared by centrifugation and protein concentration determined by Bio-rad reagent (Bio-rad). 600 g of protein diluted to 1 ml with TBS was incubated at 4°C overnight with 4 g anti-p70S6-kinase rabbit polyclonal antibody (pAb) (Upstate Biotechnology). 15 l Protein A slurry (Sigma) was added and rotated for a further 2 h at 4°C. Immunoprecipitates were recovered by washing three times in ice-cold 1× TBS at 960 g for 3 min at 4°C and assayed immediately for kinase activity using an S6 kinase assay kit (Upstate Biotechnology). A further immunoprecipitation using only Protein A slurry was performed as a control for non-specific kinase activity. Essentially, p70S6-kinase immunoprecipitation products were incubated for 10 min at 30°C with provided pseudosubstrate and 0.06 m ␥-32 P (ATP) (New England Nucleotides, Boston, MA, USA). The reaction was stopped by spotting samples on to Whatman p81 phosphocellulose squares and washed extensively in 0.75% phosphoric acid (Sigma). The squares were counted in a ␤-counter with scintillation fluid.
PI3-kinase activity assay
PI3-kinase activity was measured essentially as described by Whitman et al. 43 PI3-kinase was immunoprecipitated from untreated and PI3-kinase inhibited samples as described for p70S6-kinase using anti-p85 rabbit pAb (Upstate Biotechnology). Immunoprecipitation products were incubated with 20 g phosphatidylinositol (Sigma), resuspended by sonication in 10 mm Tris (pH 7. 
Bcl-2 family immunoprecipitations
Untreated and PI3-kinase inhibited cells (10 × 10 6 /ml) were lysed in 300 l Tris buffer (142.5 mm KCl, 5 mm MgCl 2 . 6H 2 O, 10 mm Hepes (pH 7.2), 1 mm EGTA, 0.2% NonidetP-40, 1× PMSF, 1× protease cocktail inhibitors). Target proteins were immunoprecipitated with 4 g of primary antibody from 800 g cell extract for Bcl-X L (anti Bcl-X rabbit pAb (Transduction Laboratories, Lexington, KY, USA)) and Mcl-1 (anti-Mcl-1 rabbit pAb (Upstate Biotechnology)) and 400 g extract for Bcl-2 (anti-Bcl-2 murine agarose-conjugated mAb (Santa-Cruz, San Diego, CA, USA) or anti-Bcl-2 rabbit pAb (Santa-Cruz) overnight at 4°C before addition of 40 l antirabbit or anti-mouse IgG whole molecule agarose (Sigma) for 1 h at 4°C. Immunoprecipitation with agarose-conjugated Bcl-2 mAb was a single-step procedure requiring incubation with antibody for 2 h at 4°C prior to washing. Western blotting was carried out as described, using 15% SDS-PAGE for optimum resolution of Bcl-2 family members. Immunoblots were probed with anti-Bcl-X L mouse mAb (Transduction Laboratories) at 1:500 dilution, anti-Mcl-1 rabbit pAb (Upstate Biotechnology) at 1 g/ml, anti-Bcl-2 murine mAb (Dako) at 1:50 dilution, or anti-Bcl-2 rabbit pAb (Santa-Cruz) at 1:200 dilution, anti-Bad mouse mAb (Transduction Laboratories) at 1:250 dilution, anti-Bax rabbit pAb (Upstate Biotechnology) at 1 g/ml.
Results
To investigate the potential role, if any, of the individual kinases and signalling pathways regulated by Ras in cytotoxic drug-induced apoptosis, we treated HL60 cells with varying concentrations of six cytotoxic drugs (etoposide, doxorubicin, mitoxantrone, actinomycin D, cycloheximide and camptothecin), of which etoposide and mitoxantrone are commonly used in the treatment of AML. 44 Doxorubicin has previously been used in treatment regimens but at present is much less prevalent due to its cardiotoxicity. Daunorubicin is now the anthracycline of choice in treatment protocols. 44, 45 The percentage of apoptosis induced by each drug was established, both alone and in combination with a kinase inhibitor. In each case, the inhibitors were used at concentrations which gave optimal kinase inhibition without inducing apoptosis over the course of treatment. Similar results to those detailed below were also obtained with actinomycin D and cycloheximide (data not shown).
ERK signalling does not contribute to cytotoxic druginduced apoptosis in myeloid leukaemia
We initially investigated the potential involvement of the ERK cascade in protecting against cytotoxic drug-induced apoptosis. We titrated the ERK inhibitor, apigenin 46 to establish the concentration of apigenin which would give maximum inhibition of ERK without inducing apoptosis, ie 500 nm apigenin (data not shown). ERK is activated following phosphorylation by the upstream kinase MAP-kinase-kinase. 8 Therefore, ERK phosphorylation levels can be directly correlated with its activity. We first established the extent of endogenous ERK phosphorylation in untreated cells and confirmed that this could be significantly reduced by treating with 500 nm apigenin (Figure 1a) . Figure 1a , lane 1, demonstrates that a proportion of the endogenous ERK2 has an increased molecular weight representative of phosphorylated ERK. Using densitometric analysis we found that this phosphorylated ERK band is reduced by 57% following incubation with 500 nm apigenin ( Figure 1a , lane 2). We next measured the percentage apoptosis induced by a range of concentrations of each cytotoxic drug, both alone and in combination with 500 nm apigenin (Figure 1b) . Treatment with apigenin and cytotoxic drug did not result in an increase in apoptosis when compared to levels of apoptosis induced by drug alone, suggesting that drug resistance in these cells is independent of ERK signalling. Thus, Figure 1a and b collectively indicate that although ERK2 activity is inhibited by apigenin, this does not result in sensitisation to cytotoxic drugs, suggesting that ERK signalling does not contribute to drug resistance in this cell line.
Inhibition of PI3-kinase significantly increases susceptibility to cytotoxic drug-induced apoptosis
PI3-kinase may be activated by Ras 34 and is reported to impart a strong survival signal 47, 48 potentially raising the cellular tolerance threshold for apoptosis. We have investigated whether PI3-kinase signalling influences drug-induced apoptosis by employing two well-characterised PI3-kinase inhibitors, LY294002 49 and wortmannin 50 to obstruct this pathway. We titrated LY294002 and wortmannin in HL60 cells to find the concentration of each drug which would give maximal inhibition of PI3-kinase without inducing apoptosis (data not shown). We then carried out a kinase assay to confirm that these inhibitor concentrations did inhibit PI3-kinase activity (30 m LY294002 and 500 nm wortmannin). PI3-kinase- mediated phosphorylation of phosphatidylinositol results in formation of phosphatidylinositol 3 phosphate (PI3P). We investigated PI3-kinase activity by measuring the levels of PI3P formed by PI3-kinase from untreated and LY294002 or wortmannin-treated samples. PI3-kinase was immunoprecipitated from untreated cells and cells which had been incubated for 4 h with 30 m LY294002 or 500 nm wortmannin. The production of PI3P was found to be completely inhibited by 30 m LY294002 significantly reduced by 500 nm wortmannin as compared to untreated cells (Figure 2a) . Levels of apoptosis induced by cytotoxic drug alone and in combination with 30 m LY294002 (Figure 2b ) or 500 nm wortmannin ( Figure 2c ) were then measured. In each case sensitivity to cytotoxic drug-induced apoptosis was increased between 2-and 5-fold in the presence of PI3-kinase inhibitors. These data suggest that inhibition of PI3-kinase greatly potentiates drug-induced apoptosis, a finding which may prove highly significant with regard to clinical response. Thus PI3-kinase may be an important contributor to drug resistance in myeloid leukaemia. To elucidate the pathway by which PI3-kinase may contribute to chemoresistance we examined the role played by two well-characterised mediators of PI3-kinase signalling, p70S6-kinase and PKB. 27 ,51
Leukemia
Inhibition of p70S6-kinase does not sensitise cells to cytotoxic drug-induced apoptosis
p70S6-kinase has previously been implicated as a downstream mediator of both Ras survival signals 35 and PI3-kinase. 51 Thus, the specific inhibitor rapamycin 52 was used to inhibit p70S6-kinase signalling and investigate its contribution to drug resistance. As before, we titrated rapamycin to find the concentration of the inhibitor which would maximally inhibit p70S6-kinase without inducing apoptosis, ie 100 nm. Downregulation of p70S6-kinase activity by 100 nm rapamycin was confirmed as described in Materials and methods (Figure 3a) . The level of cytotoxic drug-induced apoptosis was then assessed in the presence or absence of rapamycin (Figure 3b) . However, p70S6-kinase inhibition did not result in any detectable sensitisation to drug-induced apoptosis suggesting that the role played by PI3-kinase in enhancing drug resistance is not mediated by p70S6-kinase.
PKB/Akt is significantly dephosphorylated on inhibition of PI3-kinase
Following the apparent lack of involvement of p70S6-kinase, we investigated the role of PKB/Akt as the potential effector of PI3-kinase-mediated chemoresistance. As there is no inhibitor of PKB commercially available, we examined the effects of PI3-kinase inhibition on the phosphorylation status of PKB which has been directly related to its activity. 27, 29 There is currently immense interest in PI3-kinase and PKB as they represent the only characterised survival pathway which has been directly linked to a member of the Bcl-2 family, the proapoptotic molecule, Bad. 28, 53 The expression level of PKB in HL60 cells is shown in Figure 4 , upper panel. The middle panel illustrates the level of phosphorylated PKB in untreated, PI3-kinase inhibited and p70S6-kinase inhibited cells. Lane 1 (middle panel) shows that there is a high level of phosphorylated PKB in untreated control cells, while lanes 2 and 3 which are treated with LY294002 and wortmannin, respectively, show substantial dephosphorylation of PKB, consistent with reports that inhibition of PI3-kinase signalling prevents PKB phosphorylation and activation. 27, 29 Treatment with rapamycin (lane 4) did not effect the phosphorylation status of PKB, confirming that p70S6-kinase and PKB lie on separate pathways downstream of PI3-kinase. Figure 4 , lower panel, probed for action confirms equal loading of samples. As our data demonstrate that inhibition of PI3-kinase not only induces a marked increase in apoptosis on cytotoxic drug treatment, but also results in dephosphorylation and thus inactivation of PKB, we investigated this survival pathway further downstream at the Bcl-2 family of apoptotic regulators, initially considering interactions with Bad.
Inhibition of PI3-kinase does not lead to Bad heterodimer formation with Bcl-X L , Bcl-2 or Mcl-1
To investigate the role, if any, played by the pro-apoptotic Bcl-2 family member Bad in cytotoxic drug-induced apoptosis, we again employed the PI3-kinase inhibitors LY294002 and wortmannin. Following the inhibition of PI3-kinase we searched for evidence of Bad heterodimer formation. Bad has previously been reported to preferentially dimerise with and negate the survival activity of Bcl-X L . 54 Thus, we immunoprecipitated Bcl-X L from untreated and PI3-kinase inhibited samples, resolved the immunoprecipitation products and whole cell extract by SDS-PAGE and probed the resulting immunoblot for Bcl-X L and Bad (Figure 5a ). Although both Bad and Bcl-X L were present in the lysate, we were unable to detect binding of Bad to Bcl-X L upon inhibition of PI3-kinase despite considerable enrichment of Bcl-X L by immunoprecipitation. As Bcl-X L is poorly expressed in HL60 cells compared to Bcl-2, we considered that Bad may preferentially bind Bcl-2 following PI3-kinase inhibition. Thus, we immunoprecipitated Bcl-2, from control and PI3-kinase inhibited samples, separated the immunoprecipitation product and whole cell lysate by SDS-PAGE and probed the resulting blot for both Bcl-2 and Bad (Figure 5b ). Yet again, despite high levels of Bcl-2 being immunoprecipitated there was no evidence that Bad binds Bcl-2 following PI3-kinase inactivation.
Mcl-1, another anti-apoptotic member of the Bcl-2 family, is closely regulated by survival signals and is reported to prolong survival under adverse conditions. 55, 56 Mcl-1 has also been shown to correlate with resistance to chemotherapy in myeloid leukaemias and to have elevated expression at leukaemic relapse. 57 Hence, we wished to investigate if the expression level of Mcl-1 or its binding to Bcl-2 counterparts was altered following inhibition of survival signals from PI3-kinase/PKB. Analogously to Bcl-X L and Bcl-2 immunoprecipitations, Mcl-1 protein levels were greatly enriched by immunoprecipitation (Figure 5c ) with low levels of Mcl-1 and Bad detected in lysates. However, we could find no indication that Bad and Mcl-1 formed heterodimers after inhibition of PI3-kinase. The immunoblots also emphasise the notable differences in expression levels between Bcl-2 family members in this cell line. For these immunoprecipitations we employed conditions previously described to preserve Bcl-2 family heterodimer interactions. 58, 59 As we were unable to detect any alterations in Bcl-2 family member heterodimers, we investigated the effects of PI3-kinase inhibition on phosphorylation status of Bad. Using immunoblotting and an antibody which recognises only Bad which is phosphorylated at Ser136, the site phosphorylated by PKB, 53 we found that the phosphorylation status of Bad is not significantly changed following PI3-kinase inhibition ( Figure  5d, lower panel) . The upper panel (Figure 5d ) probed for actin represents the protein loading pattern. To confirm that the phospho-Bad (Ser136) antibody is specific for phosphorylated Bad, we employed phospho-and nonphospho-Bad control proteins, supplied with the antibody, as positive and negative controls, respectively (Figure 5e ). Thus, inhibition of PI3-kinase which results in dephosphorylation of PKB does not lead to dephosphorylation of pro-apoptotic Bad. 
Pro-apoptotic bax, binds minimally to Bcl-2 and Mcl-1, independently of PI3-kinase signalling status
Our data suggest that the majority of Bcl-2 is unbound by Bad and is therefore unlikely to be affected by its pro-apoptotic influence. At this point we considered that either PI3-kinase or PKB may have other as yet unknown targets which could influence interactions between other pro-apoptotic Bcl-2 family members, for example, Bax. We therefore investigated the relationship between Bcl-2 and Bax after PI3-kinase inhibition, as Bax has a considerably higher expression level than Bad in these cells. There are also reports that the ratio of Bax/Bcl-2 binding determines the fate of the cell. 60 Again, cells were incubated in the presence and absence of LY294002 and wortmannin, Bcl-2 immunoprecipitated, the
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Figure 4
PI3-kinase inhibition resulted in significant dephosphorylation of PKB. Total cellular PKB levels were unchanged following a 4 h incubation with either PI3-kinase or p70S6-kinase inhibitors, upper panel. Treatment with PI3-kinase inhibitors resulted in considerable reduction in phosphoPKB levels, compared to those of control or rapamycin treated cells, middle panel. Lower panel, immunoblot was probed for actin to verify equal protein loading. Lane 1, untreated control cells (C); lane 2, +30 m LY294002 (L); lane 3, +500 nm wortmannin (W); lane 4, +100 nm rapamycin (R).
immunoprecipitation product and whole cell extract probed for Bcl-2 and Bax. Although heterodimerisation between Bcl-2 and Bax could be demonstrated, no discernible alteration in Bcl-2/Bax binding was evident following PI3-kinase inhibition (Figure 6a ). It was notable that despite Bcl-2 being greatly enriched by immunoprecipitation as compared to lysate only a fraction was associated with Bax.
As Mcl-1 has previously been reported to bind to Bax 61 we also assessed binding of Bax to Mcl-1 under identical conditions (Figure 6b ). Mcl-1 was greatly enriched on immunoprecipitation but binds weakly to Bax, independently of PI3-kinase signalling status. It is apparent from these studies with Bcl-2, Bcl-X L and Mcl-1 that the majority of these proteins are largely unassociated with the pro-apoptotic Bad or Bax in this cell type and this is irrespective of signalling through PI3-kinase.
Discussion
The multiple roles of Ras in cell growth, survival, differentiation and apoptosis are well documented. [7] [8] [9] Deregulation of Ras, its regulators or downstream signalling proteins, Raf and ERK can lead to the breakdown of these tightly controlled pathways and leukaemogenesis. 15, 20 Our results did not concord with previous accounts of Raf/ERK protection against apoptosis inducing stimuli. 30, 32 Inhibition of ERK activity did not influence the response of HL60 cells to cytotoxic druginduced death, indicating that ERK signalling does not contribute to inherent drug resistance. A possible reason for this discordance is that many reports citing Raf and ERK protection against apoptosis were shown under conditions where the kinases under investigation were overexpressed and therefore may not be fully representative of the role of this kinase at physiological levels.
This study has shown that inhibition of PI3-kinase by LY294002 or wortmannin results in a 2-to 5-fold sensitisation to cytotoxic drug-induced apoptosis, suggesting that PI3-kinase signalling prevents efficient induction of apoptosis by cytotoxic drugs. To elucidate the pathway by which PI3-kinase signalling may protect from cytotoxic drug-induced death, we investigated the role played by the major downstream mediators of PI3-kinase, p70S6-kinase and PKB. 27, 48, 51 Inhibition of p70S6-kinase by rapamycin did not increase susceptibility to cytotoxic drug-induced apoptosis, suggesting that the role played by PI3-kinase in drug resistance is independent of p70S6-kinase. PKB has been reported to protect from apoptotic insult in a variety of cell lines. 27, 29 We have shown that PKB is dephosphorylated after treatment with the PI3-kinase inhibitors LY294002 and wortmannin, suggesting that PKB may potentiate drug-induced apoptosis in this cell line. Thus, we investigated the relationship between PKB and its downstream target Bad. While inactivation of PI3-kinase rendered HL60 cells significantly more susceptible to apoptosis by cytotoxic drugs and induced dephosphorylation of PKB, we were unable to detect binding of Bad to either Bcl-X L or Mcl-1, or the more abundantly expressed Bcl-2. Furthermore, analysis of Bad phosphorylation status resulted in no detectable alterations in phosphorylation levels following PI3-kinase inhibition. Such dissociation between PKB signalling and Bad phosphorylation has also been described by Hinton and Welham 62 who proposed that the capacity of particular cytokines to promote survival does not always correlate with PKB and Bad phosphorylation, and that the relationship between PKB, Bad and survival is cytokine and cell-type specific. Similar findings were also reported by Scheid and Duronio. 63 It is also interesting to note that Bad is poorly expressed in hematopoietic and lymphoid tissues as compared to many other tissue types 64 and so is perhaps less likely to play an important role in these cells.
We then considered the possibility that there may be alternative targets of PI3-kinase/PKB which could mediate other Bcl-2 family interactions. Both Bcl-2 and Bax are highly expressed in HL60 cells and the ratios of these two proteins have previously been reported to determine the fate of a cell. 60 Consequently, we examined the extent of Bcl-2/Bax binding and found that only a fraction of Bcl-2 was associated with Bax, independently of PI3-kinase signalling status. We also investigated the nature of Mcl-1 binding to Bax, detecting only low levels of interaction which were unaltered following PI3-kinase inhibition. Thus Bcl-2 and Mcl-1, elevated levels of which correlate with poor response to chemotherapy are predominantly unassociated with the pro-apoptotic mediators, Bax or Bad in HL60 cells. These results imply that the protec-tive effect of Bcl-2 in these cells may be due to the fact that the majority of Bcl-2 is free of its most notable binding partners, Bad and Bax, and that mechanisms other than simple dimerisation of the Bcl-2 family may be required for regulation of apoptosis. This theory is supported by studies which also challenge the dogma of heterodimerisation. 59, 65, 66 It has also recently been reported that protection from apoptosis is dependent not on Bcl-2/Bax heterodimerisation but on the amount of unbound Bcl-2 present within the cell. 58 Bcl-2 phosphorylation in haemopoietic cells is associated with survival and the suppression of apoptosis. 67, 68 It is likely that these survival factor regulated kinase cascades as well as maintaining high expression levels of Bcl-2, 69 could also control its phosphorylation status, possibly influencing interactions between the Bcl-2 family and targets such as Apaf-1, 70 thereby repressing apoptosis. Alternatively, inhibition of PI3-kinase may abolish the effects of unknown proteins distinct from the Bcl-2 family, priming the cells for death on treatment with cytotoxic drugs. Recently described targets of PKB could also be involved in chemoresistance. Active PKB has been shown to inhibit proteolytic processing of procaspase 9, 71 and to sequester the forkhead family of transcription factors away from target genes, such as Fas ligand. 72 Furthermore, PKB, but not PI3-kinase, is cleaved by caspase action on induction of apoptosis 73 underlining the importance of this kinase in promoting survival, and possibly drug resistance.
The sensitisation to drug-induced apoptosis which we have demonstrated in this cell line clearly involves the inhibition of an important survival pathway. It is possible that this pathway may provide a fundamental anti-apoptotic signal in transformed cell lines which have activated Ras, or in cells with other oncogenic lesions which can directly activate PI-3 kinase. This pathway is not necessarily of major importance in transformation in all types of malignancy, where a range of proliferation and anti-apoptotic lesions have been identified. However, as Ras activation is a common activating lesion in leukaemias is possible that this survival pathway may frequently provide a co-operating anti-apoptotic/drug-resistant lesion in this group of disorders. Interestingly, another study employing a monocytic leukaemia cell line U937 has also reported that inhibition of PI-3 kinase signalling using wortmannin and LY294002 sensitised the cells to apoptosis induced by the anthracycline daunorubicin. 74 In conclusion, the results presented here highlight the importance of survival factor signalling in determining the susceptibility of leukaemic cells to cytotoxic drug-induced apoptosis and suggest a novel role for PI3-kinase and PKB in chemoresistance. We have partially elucidated a drug resistance pathway in leukaemic cells and shown that inhibition of a major mediator of survival signals, PI3-kinase, can notably sensitise cells to cytotoxic drug-induced apoptosis, a finding which may be of immense therapeutic importance. This mechanism may possibly involve PKB, but is distinct from ERK and p70S6-kinase signalling pathways. In contrast to previous reports which suggest that this pathway modulates Bcl-2 family interactions, we have found no evidence of PI3-kinasemediated alterations in heterodimer formation between the major Bcl-2 family members expressed in this cell line. However, we are currently continuing this research into elucidating the relationship between PI3-kinase and other apoptotic decision makers in this system. The sensitisation which we have demonstrated with PI3-kinase inhibitors, indicates that inhibition of survival pathways in combination with established chemotherapeutic drugs is a potent cytotoxic cocktail. Increased understanding of tissue-specific requirements for Leukemia survival, and potential exploitation of cell-type-specific pathways may yield new and more selective combination therapies. Such applications are proving effective in the treatment of multiple myeloma, where abolition of IL-6-mediated survival is the focus of many treatment protocols. 75 In summary, we have shown that the ability of cytotoxic drugs to engage cell death in leukaemic cells may be obstructed by the elevation of survival signals mediated by PI3-kinase and PKB. A better understanding of how these pathways influence survival may permit the development of a more effective and specific chemotherapeutic strategy for leukaemia.
